HighPoint Advisor Group LLC boosted its stake in Colgate-Palmolive Co. (NYSE:CL) by 12.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,377 shares of the company’s stock after buying an additional 613 shares during the period. HighPoint Advisor Group LLC’s holdings in Colgate-Palmolive were worth $402,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of CL. BLB&B Advisors LLC boosted its position in shares of Colgate-Palmolive by 8.1% in the first quarter. BLB&B Advisors LLC now owns 8,357 shares of the company’s stock valued at $590,000 after buying an additional 627 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Colgate-Palmolive by 1.1% in the first quarter. Fisher Asset Management LLC now owns 21,126 shares of the company’s stock valued at $1,505,000 after buying an additional 236 shares in the last quarter. Sigma Planning Corp boosted its position in shares of Colgate-Palmolive by 20.5% in the first quarter. Sigma Planning Corp now owns 6,442 shares of the company’s stock valued at $455,000 after buying an additional 1,095 shares in the last quarter. Dividend Asset Capital LLC boosted its position in shares of Colgate-Palmolive by 11.2% in the first quarter. Dividend Asset Capital LLC now owns 7,705 shares of the company’s stock valued at $544,000 after buying an additional 775 shares in the last quarter. Finally, QUANTRES ASSET MANAGEMENT Ltd boosted its position in shares of Colgate-Palmolive by 19.4% in the first quarter. QUANTRES ASSET MANAGEMENT Ltd now owns 3,700 shares of the company’s stock valued at $261,000 after buying an additional 600 shares in the last quarter. Institutional investors own 72.97% of the company’s stock.
Shares of Colgate-Palmolive Co. (NYSE:CL) opened at 73.46 on Wednesday. The stock’s 50 day moving average price is $73.77 and its 200-day moving average price is $72.28. The stock has a market cap of $65.49 billion, a price-to-earnings ratio of 47.30 and a beta of 0.59. Colgate-Palmolive Co. has a 52-week low of $61.40 and a 52-week high of $75.38.
Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.01. Colgate-Palmolive had a net margin of 9.04% and a return on equity of 1,980.28%. The business earned $3.85 billion during the quarter, compared to analyst estimates of $3.86 billion. During the same period in the previous year, the business posted $0.70 EPS. The company’s quarterly revenue was down 5.4% on a year-over-year basis. On average, analysts predict that Colgate-Palmolive Co. will post $2.80 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 15th. Stockholders of record on Monday, October 24th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.12%. The ex-dividend date of this dividend is Thursday, October 20th. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 100.65%.
Several research analysts have recently weighed in on CL shares. Exane BNP Paribas cut Colgate-Palmolive from an “outperform” rating to a “neutral” rating in a report on Friday, July 29th. Goldman Sachs Group Inc. restated a “neutral” rating and set a $76.00 target price (up from $74.00) on shares of Colgate-Palmolive in a report on Friday, July 15th. JPMorgan Chase & Co. restated a “hold” rating and set a $75.00 target price on shares of Colgate-Palmolive in a report on Friday, July 29th. Zacks Investment Research cut Colgate-Palmolive from a “buy” rating to a “hold” rating in a report on Tuesday, September 20th. Finally, Atlantic Securities started coverage on Colgate-Palmolive in a report on Wednesday, June 1st. They issued an “overweight” rating on the stock. Fifteen research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $74.46.
In other Colgate-Palmolive news, insider Patricia Verduin sold 3,834 shares of the business’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $71.85, for a total transaction of $275,472.90. Following the completion of the transaction, the insider now directly owns 55,013 shares of the company’s stock, valued at approximately $3,952,684.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ellen M. Hancock sold 4,584 shares of the business’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $74.82, for a total transaction of $342,974.88. Following the transaction, the director now directly owns 203,632 shares of the company’s stock, valued at $15,235,746.24. The disclosure for this sale can be found here. 1.05% of the stock is currently owned by insiders.
Colgate-Palmolive Company (Colgate) is a consumer products company, whose products are marketed in over 200 countries and territories throughout the world. The Company’s segments include Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through over five geographic segments, which include North America, Latin America, Europe/South Pacific, Asia and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Co. (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive Co. and related companies with MarketBeat.com's FREE daily email newsletter.